2024-514746-36-00招募中1 期
Phase 1 dose-escalation trial of OMTX705, an anti-fibroblast activation protein antibody-drug conjugate, as single agent and in combination with anti-PD-1 in patients with advanced solid tumors
Oncomatryx Biopharma S.L.8 个研究点 分布在 1 个国家目标入组 120 人开始时间: 2024年7月1日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 120
- 试验地点
- 8
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Chief Medical Officer
Scientific
Oncomatryx Biopharma S.L.
研究点 (8)
Loading locations...
相似试验
终止
1 期
A Phase I, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of A-337 in Patients with Advanced Solid TumorsCancerACTRN12617001181392INC Research Pty Ltd4
招募中
1 期
Phase I Study of the Volitinib (HMPL-504) in Patients With Advanced Solid TumorsHistologically or cytologically documented, incurable, locally advanced, or metastatic solid malignancy that has progressed on, or failed to respond to, at least one prior systemic therapyCancer - Any cancerACTRN12613000133730Hutchison Medipharma Ltd25
招募中
1 期
A Phase I, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of IMP4297 in Patients with Advanced Solid TumorsAdvanced solid tumoursCancer - BreastCancer - Ovarian and primary peritonealCancer - ProstateACTRN12616000689471IMPACT Therapeutics Australia Pty Ltd30
已完成
不适用
Phase I dose-escalation trial for the combination of sorafenib with interleukin-2 (IL-2) in patients with clear cell renal cancerNL-OMON30060KI-AV30
进行中（未招募）
不适用
A Phase I/II, open-label, dose escalation trial to evaluate the safety, pharmacokinetics, and pharmacodynamics of RAF265 (CHIR-265) administered orally to patients with locally advanced or metastatic melanomalocal advanced or metastatic melanomaMedDRA version: 9.1Level: LLTClassification code 10027481Term: Metastatic melanomaEUCTR2007-005367-10-NLovartis Pharma Services AG211